NCT07454941Enrolling by invitation
Artificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology Omics
Source: ClinicalTrials.gov · Last updated 6 Mar 2026
Brief summary (registry, in English)
This study aims to build upon previous research by using artificial intelligence methods to fuse multimodal data from imaging and pathology to construct a predictive model for HER2 expression in urothelial carcinoma. The model's performance will be validated and optimized using a multicenter cohort study, ultimately achieving accurate and rapid prediction of HER2 expression. This will guide precise decision-making for further HER2-targeted therapy and improve patient prognosis. Big data analysis and deep learning will also assist physicians in more accurately diagnosing the disease and developing personalized treatment plans. The research findings will promote the integration and development of artificial intelligence technology with the healthcare industry in the application of multimodal data from clinical, imaging, and pathology perspectives.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 4000 (estimated)
- First submitted
- 2 Mar 2026
- Start date
- 2 Mar 2026
- Primary completion date
- 3 Jun 2028
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Diseases
- Bladder cancer
- NCT number
- NCT07454941
What you commit to
- Study type: Observational
- Planned participants: 4000
- From 2 Mar 2026 to the primary completion date, 3 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindications to MRI, such as presence of metallic implants or claustrophobia.
- Patients who have received neoadjuvant therapy.
Other illness
- Patients with a history of other malignant tumors.
Other
- Patients with missing baseline clinical or pathological information.
- Patients with mixed or non-urothelial carcinoma pathology.
Who the study is looking for
- Age ≥ 18 years.
- Patients pathologically diagnosed with urothelial carcinoma.
- Possession of pre-biopsy or pre-operative multiparametric MRI raw data.
- Possession of corresponding paraffin-embedded tissue blocks and digital whole-section images.
- Possession of HER2 status report confirmed by immunohistochemistry.
- Signed informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences Beijing Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.